2122. In Vitro Activity of Cefepime-Taniborbactam Against Clinically Significant Gram-Negative Bacteria Isolated from Patients with Cancer

BACKGROUND: Gram negative (GN) bacterial infections are on the rise in patients with cancer (PWC). There is an urgent need for new therapies to address the rise of infections caused by multidrug resistant (MDR) GN pathogens. Taniborbactam is a β-lactamase inhibitor in combination with cefepime may o...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerges, Bahgat Z, Truong, Y Lan, Rosenblatt, Joel, Hachem, Ray Y, Chaftari, Anne-Marie, Shelburne, Samuel A, Raad, Issam I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677328/
http://dx.doi.org/10.1093/ofid/ofad500.1745

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677328/
http://dx.doi.org/10.1093/ofid/ofad500.1745

Ejemplares similares